The Centre for Cellular and Molecular Platforms (C-CAMP), India’s premier bio-innovation hub recently signed an Letter of Intent (LOI) with Tokyo, Japan-based venture capital firm Beyond Next Ventures (BNV), which is also one of the leading independent accelerators in Japan dedicated to incubation investment in technology start-ups.

The aim of this collaboration is to encourage and promote the best deep science innovations in the field of Life Sciences and Biotechnology in India.

The two organizations intend to create the C-CAMP – BNV Innovation Hub (CBIH) which will largely focus on facilitating Japanese investment of up to 5 million USD in Indian start-ups working on exciting technologies in the Life Sciences and Biotech domain.

This hub also aims to support start-ups in both the regions through exchange of human resources and technologies and through other facilitation programs and events to connect skilled talent, entrepreneurs and other stakeholders in both regions.

C-CAMP has over the last few years interacted with over 500 start-ups and supported over 100 of these through funding, incubation and mentorship.

Dr. Taslimarif Saiyed, CEO & Director, C-CAMP said “C-CAMP has been identifying and supporting the most exciting early stage innovations and now looks forward to nurture many more such high-risk high-return innovations at an early stage through this collaboration with Beyond Next Ventures. This will be a fantastic start to build Indo-Japan collaborations for high-end innovations.”

Mr. Tsuyoshi Ito CEO, BNV said “We are very excited to jointly launch the “C-CAMP Beyond Next Ventures Innovation Hub” (“CBIH”) in collaboration with the top incubator in India C-CAMP. As the top accelerator and VC in Japan, we look forward to combining our experience and extensive network with C-CAMP to support new innovations in Japan and India. Through this collaboration, we plan to make full-fledged venture investments into the life sciences field of India and contribute to the industrial and economic development in India in the future."

Established in August 2014, BNV is an independent accelerator dedicated to incubation investment in technology startups. It is one of the few leading companies in the field in Japan with a wealth of investment experience ranging from support for commercialization of university seeds to venture investment, growth support, and excellent operation results, and JSTs university new industry creation program. It has been recognized as a business promoter at (START) and EDO's R & D venture support project. The first fund established in February 2015, and the second fund established in October 2018, totals less than 15 billion yen, operating as the country's largest fund as an accelerator, and will be invested in a large number of technology startups, supporting its commercialization and
growth.

BNV is actively working on commercialization support other than funding, "BRAVE acceleration program", for researchers / entrepreneurs such as universities and research institutes aiming to commercialize innovative technologies, matching with management human resources candidates, knowledge and human resources for commercialization realization We provide network and growth funds. In addition, a program called “Blockbuster TOKYO” That supports contracting from Tokyo and supports entrepreneurship in drug discovery and medical ventures and growth of drug discovery and medical venture companies also operates.

In February 2019, as a base to provide start-up companies in the life sciences area with support for commercialization including research and development, BNV launched the share lab / wet lab “Beyond BioLAB TOKYO” in Chuo-ku, Tokyo.

From March 2019, BNV started to provide a co-founder matching platform "Co-founders" specialized for technical seeds and researchers at universities(URL:https://co-founders.team/)and by providing the online matching opportunities and real support, we are helping to create a strong founding team.
Advertisements

Post a Comment

أحدث أقدم
Like this content? Sign up for our daily newsletter to get latest updates.